New immune cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT07198867
Summary
This early-stage study is testing the safety and initial effectiveness of a new CAR-T cell therapy called A-CAR028 for adults with acute myeloid leukemia (AML) that has returned or not responded to other treatments. The study will enroll up to 20 participants to determine safe dosing and monitor how their bodies respond to the treatment. Researchers will collect modified immune cells from patients, grow them in a lab, and then infuse them back to target and fight the leukemia cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.